KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Shares Outstanding (Diluted Average) (2016 - 2025)

West Pharmaceutical Services' Shares Outstanding (Diluted Average) history spans 17 years, with the latest figure at $72.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 1.36% year-over-year to $72.7 million; the TTM value through Dec 2025 reached $72.7 million, down 1.36%, while the annual FY2025 figure was $72.7 million, 1.36% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $72.7 million at West Pharmaceutical Services, roughly flat from $72.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $76.3 million in Q4 2021 and bottomed at $72.5 million in Q2 2025.
  • The 5-year median for Shares Outstanding (Diluted Average) is $75.5 million (2023), against an average of $74.8 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) grew 0.66% in 2021 before it dropped 2.25% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $76.3 million in 2021, then dropped by 0.66% to $75.8 million in 2022, then dropped by 0.66% to $75.3 million in 2023, then decreased by 2.12% to $73.7 million in 2024, then fell by 1.36% to $72.7 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Shares Outstanding (Diluted Average) are $72.7 million (Q4 2025), $72.6 million (Q3 2025), and $72.5 million (Q2 2025).